Alvin joined Catamaran as President and CEO in February 2021.  He is an experienced physician and biopharma executive with a track record of building and leading companies that develop therapeutics addressing significant unmet medical needs.  Most recently, Alvin was CEO of Disarm Therapeutics, a private neuroscience company that was acquired by Eli Lilly in 2020.  Prior to Disarm, Alvin was CEO of Enzyvant Therapeutics, a company developing cell/tissue-based regenerative medicines for rare diseases.  He previously held senior leadership roles at Retrophin and Pfizer, where he was the Chief Operating Officer of the Pfizer Rare Disease Research Unit.  Alvin began his industry career as a strategy consultant at McKinsey & Co. and LEK Consulting.  He holds an MD from the University of Alabama, an MBA from the Kellogg School of Management, and a BA from Vanderbilt University.  Alvin completed his residency training in internal medicine at the Massachusetts General Hospital.

Dave joined Catamaran as Vice President, Finance in June 2021. He has worked at growing biotech companies and built a track record of progressive operational finance experience. Most recently, Dave was Senior Director, Finance at Akebia Therapeutics, a publicly-traded, fully integrated biopharmaceutical company that develops and commercializes renal therapeutics. Prior to Akebia, he served as the Senior Director of Finance & Accounting and Controller at Keryx Biopharmaceuticals. While at Keryx, Dave was a key finance partner in the company’s strategic merger with Akebia. He began his career at PwC in the assurance practice, supporting clients in the life sciences and healthcare industries. Dave holds an MS in Accounting and a BS in Finance and Accounting from the Carroll School of Management at Boston College and is a certified public accountant in the Commonwealth of Massachusetts.

Dominic joined Catamaran as Senior Director, In Vivo Pharmacology in March 2021. Prior to joining Catamaran, Dominic led the in vivo pharmacology teams at Cobalt Biomedicine and subsequently Sana Biotechnology. In those roles, Dominic focused on proof of concept and candidate selection studies for gene and engineered cell therapeutic approaches in a variety of disease indications including oncology, rare monogenic hepatic disorders and acute liver failure. Prior to his gene/cell therapy experience, Dominic managed external preclinical studies for Catabasis Pharmaceuticals with a specific focus on NASH, Duchenne’s Muscular Dystrophy, and Cystic Fibrosis. Dominic began his post academic career at LeukoSite where he focused on integrins and chemokine receptors as therapeutic targets to modulate homing and recruitment of specific leukocyte subsets to sites of inflammation involved in the pathogenesis of multiple disease indications. He conducted his postdoctoral training in the Immunobiology Section at Yale University where he studied mechanisms of peripheral anergy of T cells. Dominic holds a PhD in Immunology from Tufts University, and he earned an MS in Microbiology and an AB in Chemistry from Rutgers University.

Joe joined Catamaran as Vice President, Technical Operations and Manufacturing, in August 2021. He brings more than twenty-five years of experience in cell therapy development and GMP manufacturing of cell and gene therapies. Prior to Catamaran, Joe served as Senior Director, Manufacturing at City of Hope’s Center for Biomedicine and Genetics where he led viral vector and cell therapy process development and GMP manufacturing for oncology and regenerative medicine projects for City of Hope clinical trials and external clients. Before his role at City of Hope, he worked at Stanford’s Cardiovascular Institute as Assistant Director of Translational Research, working to bring stem cell-derived therapies for heart failure to the clinic.  Joe began his career in biotechnology at Geron Corporation, where he headed up basic research into pluripotent stem cell-derived therapies for diseases ranging from spinal cord injury to diabetes to heart failure. Joe performed his postdoctoral research at UCSF in early embryological development. He holds a PhD in Cell and Developmental Biology from Harvard and a BS in Biology from University of Pennsylvania.

Chris joined Catamaran as Chief Medical Officer in November 2020. He brings more than two decades of clinical and laboratory experience in oncology. Prior to Catamaran, Chris was Chief Medical Officer of Rubius Therapeutics. Previously, Chris was a Senior Vice President and Head of the Cancer Epigenetics Discovery Performance Unit at GlaxoSmithKline. He was responsible for the overall strategy, as well as the identification and validation of new targets and advancing novel therapies through clinical proof of concept. Under his leadership the group brought four compounds into clinical development. While at GSK, Chris also led the clinical development of Votrient® (pazopanib). Prior to GSK, he led the clinical development of MK-4827, which became Tesaro’s Zejula®. Prior to Merck, Chris led a laboratory focus on signal transduction at Harvard Medical School and the Beth Israel Deaconess Medical Center for 14 years. He is board certified in medical oncology. Chris holds a BS from Stanford University and MD and PhD (pharmacology) degrees from the University of Southern California. He completed a residency in internal medicine at UT Southwestern, his hematology/oncology fellowship at Massachusetts General Hospital, and a post-doctoral fellowship in Lewis Cantley’s laboratory.

Vipin joined Catamaran as Chief Scientific Officer in March 2020. Along with his deep expertise in researching and developing cell therapies for cancer, Vipin has over two decades of experience in the biotech and pharmaceutical industry. Most recently, he co-founded and led Discovery Research at Obsidian Therapeutics. Vipin’s work at Obsidian led to the development of Obsidian’s cytoDRive platform, which broadened the therapeutic reach of cell and gene therapies. Prior to Obsidian, Vipin was a member of the founding team and Head of Biology at Serien (formerly Raze) Therapeutics and an Entrepreneur in Residence at Atlas Venture. At Raze, Vipin’s research was focused on discovering novel anticancer agents by targeting unique vulnerabilities of rapidly growing tumors. Earlier in his career, Vipin spent more than a decade working in the pharmaceutical industry at GSK, Pfizer, and Wyeth, where his research spanned novel small molecule, peptide, nucleic acid, and protein therapeutics across a wide range of therapeutic areas. Vipin holds a PhD in biochemistry from Brandeis University and an MBA from Yale School of Management.